Related Experiment Videos
A68930: a potent agonist selective for the dopamine D1 receptor
M P DeNinno1, R Schoenleber, R MacKenzie
1Neuroscience Research Division, Abbott Laboratories, Abbott Park, IL 60064.
European Journal of Pharmacology
|June 25, 1991
Summary
A novel compound, A68930, acts as a potent dopamine D1 receptor agonist, showing significant effects in animal models relevant to Parkinson's disease. Its specific molecular structure is key to its D1 receptor selectivity.
Area of Science:
- Neuropharmacology
- Dopamine Receptor Research
Background:
- Dopamine receptors, particularly D1, are crucial in regulating motor control and are implicated in neurological disorders.
- Developing selective D1 receptor agonists is a therapeutic goal for conditions like Parkinson's disease.
Purpose of the Study:
- To characterize the pharmacological profile of A68930, a novel isochroman derivative.
- To evaluate the in vivo efficacy of A68930 in rodent models of dopamine receptor function and Parkinson's disease.
Main Methods:
- In vitro receptor binding and functional assays to determine affinity and efficacy at D1 and D2 dopamine receptors.
- In vivo behavioral studies in lesioned and normal rats, including rotational behavior and locomotor activity.
- Biochemical assays measuring 2-deoxyglucose uptake in specific brain regions.
Main Results:
- A68930 demonstrated high potency and selectivity for the D1 dopamine receptor over the D2 receptor in vitro.
- In vivo, A68930 induced prolonged contralateral turning in 6-OHDA lesioned rats, an effect blocked by D1 antagonists.
- The compound also increased 2-deoxyglucose uptake in the substantia nigra, pars reticulata, and caused hyperactivity in normal rats.
Conclusions:
- A68930 is a potent and selective full agonist of the D1 dopamine receptor.
- Its pharmacological profile suggests potential therapeutic utility in conditions associated with D1 receptor dysfunction, such as Parkinson's disease.